文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

重型再生障碍性贫血患者接种SARS-CoV-2疫苗的临床结局与免疫应答

Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia.
PubMed 文献 · Br J Haematol · 2022-09-21

研究纳入50例既往接受免疫抑制治疗的重型再生障碍性贫血(SAA)患者,评估COVID-19疫苗接种对血液学指标和疾病状态的影响,并分析体液和细胞免疫应答。接种前后血红蛋白、血小板、淋巴细胞和中性粒细胞计数无显著差异,接种后复发3例(6%);90%(28/31)可检测到体液应答,CD4+ Th1优势T细胞应答与对照组定性相似。

要点

  • SAA患者接种COVID-19疫苗前后血红蛋白、血小板、淋巴细胞及中性粒细胞计数无显著差异。
  • 接种后复发3例(6%),复发定义为计数进行性下降需治疗。
  • 90%(28/31)可检测到体液应答,即使接受环孢素者也有10/11(90.1%)可检测到。

核心结论

  • 既往接受免疫抑制治疗的SAA患者接种COVID-19疫苗后表现出适当的体液和细胞免疫应答,接种后真性复发罕见。

研究设计与样本

  • 研究纳入50例既往接受免疫抑制治疗(IST)的重型再生障碍性贫血(SAA)患者,评估COVID-19疫苗接种对血液学指标和疾病状态的影响,并分析体液和细胞免疫应答。

主要发现

  • 接种完成前后血红蛋白(p = 0.52)、血小板计数(p = 0.67)、绝对淋巴细胞计数(p = 0.42)和中性粒细胞计数(p = 0.98)无显著差异。
  • 接种后复发(定义为计数进行性下降需治疗)发生在3例患者(6%)。
  • 通过体外血管紧张素II转化酶(ACE2)结合减少和中和试验可检测到体液应答者占90%(28/31),即使接受环孢素者也有10/11(90.1%)可检测到。
  • 27例SAA患者与10例对照者的刺突特异性T细胞应答比较显示,CD4+ Th1优势应答定性相似。
  • 接种时接受或未接受环孢素治疗的患者间CD4+(p = 0.77)或CD8+(p = 0.74)T细胞应答无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with severe aplastic anaemia (SAA) are often not vaccinated against viruses due to concerns of ineffective protective antibody response and potential for pathogenic global immune system activation, leading to relapse. We evaluated the impact of COVID-19 vaccination on haematological indices and disease status and characterized the humoural and cellular responses to vaccination in 50 SAA patients, who were previously treated with immunosuppressive therapy (IST). There was no significant difference in haemoglobin (p = 0.52), platelet count (p = 0.67), absolute lymphocyte (p = 0.42) and neutrophil (p = 0.98) counts prior to and after completion of vaccination series. Relapse after vaccination, defined as a progressive decline in counts requiring treatment, occurred in three patients (6%). Humoural response was detectable in 90% (28/31) of cases by reduction in an in-vitro Angiotensin II Converting Enzyme (ACE2) binding and neutralization assay, even in patients receiving ciclosporin (10/11, 90.1%). Comparison of spike-specific T-cell responses in 27 SAA patients and 10 control subjects revealed qualitatively similar CD4+ Th1-dominant responses to vaccination. There was no difference in CD4+ (p = 0.77) or CD8+ (p = 0.74) T-cell responses between patients on or off ciclosporin therapy at the time of vaccination. Our data highlight appropriate humoural and cellular responses in SAA previously treated with IST and true relapse after vaccination is rare.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rajput RV, Ma X, Boswell KL, et al. Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia. Br J Haematol. 2022. PMID: 36128909. doi:10.1111/bjh.18456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。